Propanc Biopharma Inc (PPCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 10 | 93 | 25 | 19 | 4 |
| Receivables | 3 | 3 | 5 | 3 | 2 |
| TOTAL | $19 | $97 | $54 | $38 | $15 |
| Non-Current Assets | |||||
| PPE Net | 0 | 1 | 1 | 1 | 2 |
| Other Non-Current Assets | 41 | 47 | 53 | 55 | 65 |
| TOTAL | $41 | $47 | $54 | $56 | $67 |
| Total Assets | $60 | $144 | $108 | $94 | $82 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 115 | 115 | 116 | 48 | 51 |
| Accounts payable and accrued liabilities | 967 | 918 | 915 | 899 | 943 |
| Accrued Expenses | 624 | 744 | 616 | 449 | 524 |
| Other current liabilities | 1,041 | 742 | 619 | 499 | 598 |
| TOTAL | $3,158 | $3,060 | $2,993 | $2,822 | $3,063 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 19 | 25 | 31 | 39 | 42 |
| TOTAL | $19 | $25 | $31 | $39 | $42 |
| Total Liabilities | $3,178 | $3,085 | $3,023 | $2,862 | $3,105 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 0 | 3,288,405 | 1,763,909 | 889,746 | 677,178 |
| Common Shares | 8 | 2,621 | 1,246 | 677 | 0 |
| Retained earnings | -64,685 | -63,879 | -63,069 | -62,564 | -61,558 |
| Other shareholders' equity | 1,248 | 1,247 | 1,212 | 1,320 | 1,169 |
| TOTAL | $-3,117 | $-2,941 | $-2,915 | $-2,768 | $-3,024 |
| Total Liabilities And Equity | $60 | $144 | $108 | $94 | $82 |